BMS-279700

• Description:

  BMS-279700 is an orally active Src-family kinase p56Lck inhibitor. BMS-279700 can block the production of proinflammatory cytokines (IL-2 and TNFα) . BMS-279700 can inhibit T cell proliferation. BMS-279700 can be used for the researches of inflammation and immunology[1].

• UNSPSC:

  12352005

• Target:

  Interleukin Related; Src; TNF Receptor

• Related Pathways:

  Apoptosis; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

• Field of Research:

  Inflammation/Immunology

• Smiles:

  C[C@H](NCC1)CN1C2=CC=C3C(N4C(C(NC5=C(C=CC=C5Cl)C)=N3)=CN=C4)=N2

• Molecular Formula:

  C21H22ClN7

• Molecular Weight:

  407.90

• References & Citations:

  [1]Chen P, et al. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S) -N- (2-chloro-6-methylphenyl) -2- (3-methyl-1-piperazinyl) imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. J Med Chem. 2004 Aug 26;47 (18) :4517-29.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IL-12; Lck

• CAS Number:

  [240814-54-4]